

anti-inflammatoxy and immuno-therapy - all results

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
Immunostimulants drugs	7 studies ¹	0.72 [0.37 ; 1.43], 2 RCTs, I2=58% demonstrated inconclusive result	0.68 [0.21 ; 2.20], 1 RCT, I2=0% inconclusive result	0.78 [0.58 ; 1.05], 6 RCTs, I2=0% inconclusive result	1.61 [0.61 ; 4.25], 3 RCTs, I2=82% inconclusive result
Immunosuppressants drugs	6 studies ²	0.53 [0.22 ; 1.28], 2 RCTs, I2=78% demonstrated inconclusive result	1.39 [0.76 ; 2.54], 1 RCT, I2=0% inconclusive result	0.68 [0.48 ; 0.97], 5 RCTs, I2=0% moderate degree of certainty	-
anti-inflammatory therapies	4 studies ³	0.12 [0.01 ; 1.91], 2 RCTs, I2=69% inconclusive result	-	0.42 [0.04 ; 4.91], 2 RCTs, I2=0% inconclusive result	1.71 [0.80 ; 3.64], 1 RCT, I2=0% inconclusive result
Kinase inhibitors	1 study ⁴	-	-	-	-

Notes

¹Pandit, 2021 (CTRI/2020/06/026087) ; Shashi Bhushan, 2021 (CTRI/2020/12/029855) ; Somersan-Karakaya (Cohort 1, Cohort 1A ; Combined doses), 2021 (NCT04426695) ; Fu, 2020 (ChiCTR2000030262) ; Jagannathan, 2020 (NCT04331899) ; Libster, 2020 (NCT04479163) ; PLACID, 2020 (CTRI/2020/04/024775)

²Murugesan, 2022 () ; CORIMUNO-ANA-1, 2021 (NCT04341584) ; LIVE-AIR (Temesgen), 2021 (NCT04351152) ; Rodriguez-Garcia, 2020 (EUPAS34966) ; Cantini, 2020 () ; Capra, 2020 ()

³COL-COVID (Pascual-Figal), 2021 (NCT04350320) ; Rashad (CLARI vs SoC), 2021 () ; Ravichandran, 2021 (CTRI/2021/05/033544) ; Ravichandran, 2020 ()

⁴Covid-19 HUF, 2021 (NCT04346147)